Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 498
Filtrar
1.
Kidney Int ; 105(6): 1212-1220, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38514000

RESUMEN

Accurate assessment of the glomerular filtration rate (GFR) is crucial for researching kidney disease in rats. Although validation of methods that assess GFR is crucial, large-scale comparisons between different methods are lacking. Both transcutaneous GFR (tGFR) and a newly developed estimated GFR (eGFR) equation by our group provide a low-invasive approach enabling repeated measurements. The tGFR is a single bolus method using FITC-labeled sinistrin to measure GFR based on half-life of the transcutaneous signal, whilst the eGFR is based on urinary sinistrin clearance. Here, we retrospectively compared tGFR, using both 1- and 3- compartment models (tGFR_1c and tGFR_3c, respectively) to the eGFR in a historic cohort of 43 healthy male rats and 84 male rats with various models of chronic kidney disease. The eGFR was on average considerably lower than tGFR-1c and tGFR-3c (mean differences 855 and 216 µL/min, respectively) and only 20 and 47% of measurements were within 30% of each other, respectively. The relative difference between eGFR and tGFR was highest in rats with the lowest GFR. Possible explanations for the divergence are problems inherent to tGFR, such as technical issues with signal measurement, description of the signal kinetics, and translation of half-life to tGFR, which depends on distribution volume. The unknown impact of isoflurane anesthesia used in determining mGFR remains a limiting factor. Thus, our study shows that there is a severe disagreement between GFR measured by tGFR and eGFR, stressing the need for more rigorous validation of the tGFR and possible adjustments to the underlying technique.


Asunto(s)
Modelos Animales de Enfermedad , Tasa de Filtración Glomerular , Insuficiencia Renal Crónica , Animales , Masculino , Insuficiencia Renal Crónica/fisiopatología , Insuficiencia Renal Crónica/orina , Insuficiencia Renal Crónica/diagnóstico , Ratas , Riñón/fisiopatología , Ratas Sprague-Dawley , Estudios Retrospectivos , Fluoresceína-5-Isotiocianato/análogos & derivados , Fluoresceína-5-Isotiocianato/farmacocinética , Fluoresceína-5-Isotiocianato/administración & dosificación , Reproducibilidad de los Resultados , Eliminación Renal/fisiología , Fluoresceínas , Oligosacáridos
2.
Biochem Biophys Res Commun ; 595: 82-88, 2022 03 05.
Artículo en Inglés | MEDLINE | ID: mdl-35104704

RESUMEN

The development of ultra-long circulating nanodrug delivery systems have showed distinct advantage in maintaining the long-lasting tumor retention. Although the relationship between extended tumor retention and ultra-long plasma half-life was apparent, there was still a lack of experimental evidence to reveal the enhancement mechanism. Herein, we proposed a concept of "Sustained Irrigation" effect ("SI" effect) to elucidate that it was through sustained blood irrigation that the ultra-long circulating nanoparticles achieved long-lasting tumor retention. Besides, in order to intuitively verify the "SI" effect, we developed an "ON-OFF-ON" fluorescence switch technology. The ultra-long circulating delivery nanoparticle was constructed by encapsulating the protein with hydrophilic polymer shell. Nanoparticles with ultra-long plasma half-life (t1/2>40 h) fabricated by this method were employed as models for demonstrating the "SI" effect. The recovery of Cy5.5 fluorescence after the laser quenching meant the "fresh" Cy5.5-labeled nanoparticles were entering tumor, which confirmed the ultra-long circulating nanoparticles in blood could sustainedly irrigate to tumor. Our finding revealed the key mechanism by which ultra-long circulating NDDSs enhanced the tumor accumulation and retention, and provided experimental support for the development of ultra-long circulating delivery system in clinic.


Asunto(s)
Sistemas de Liberación de Medicamentos/métodos , Nanopartículas/administración & dosificación , Nanopartículas/química , Neoplasias Experimentales/metabolismo , Albúmina Sérica Bovina/administración & dosificación , Animales , Carbocianinas/química , Carbocianinas/farmacocinética , Línea Celular Tumoral , Fluoresceína-5-Isotiocianato/química , Fluoresceína-5-Isotiocianato/farmacocinética , Humanos , Masculino , Ratones , Microscopía Confocal , Microscopía Electrónica de Transmisión , Nanopartículas/ultraestructura , Ratas Sprague-Dawley , Albúmina Sérica Bovina/química , Albúmina Sérica Bovina/farmacocinética , Distribución Tisular
3.
Food Chem Toxicol ; 157: 112606, 2021 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-34653555

RESUMEN

Evaluating the safety of previously fabricated and effective green synthetized colloidal silver (GSCS) on the mucosal barrier structure and function is essential prior to conduct human trials. The GSCS was applied to primary human nasal epithelial cells (HNECs) grown in an air-liquid interface (ALI) culture. Epithelial barrier integrity was evaluated by measuring the transepithelial electrical resistance (TEER) and fluorescein isothiocyanate (FITC)-dextran paracellular permeability. Ciliary beat frequency (CBF) was quantified. Effects of the GSCS on cell viability and inflammation were examined through lactate dehydrogenase, the 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide viability assay and interleukin 6 (IL-6) enzyme linked immunosorbent assay. The localization and transportation of GSCS within HNECs and their HNEC-ALI cultures was assessed by transmission electron microscopy and inductively coupled plasma-mass-spectrometry, respectively. Application of GSCS to HNECs-ALI cultures for up to 2 h caused a significant reduction in the TEER values, however, it did not drop within the first 10 and 20 min for CRS and non-CRS control HNECs. The paracellular permeability, cell viability, IL-6 secretion and CBF remained unchanged. No GSCS was observed within or transported across HNECs. In conclusion, application of GSCS to HNECs is devoid of toxic effects.


Asunto(s)
Nanopartículas del Metal/toxicidad , Mucosa Nasal/efectos de los fármacos , Plata/toxicidad , Permeabilidad de la Membrana Celular , Células Cultivadas , Cilios/efectos de los fármacos , Dextranos/farmacocinética , Impedancia Eléctrica , Ensayo de Inmunoadsorción Enzimática/métodos , Fluoresceína-5-Isotiocianato/análogos & derivados , Fluoresceína-5-Isotiocianato/farmacocinética , Tecnología Química Verde/métodos , Humanos , Mucosa Nasal/citología , Plata/química
4.
Int J Biol Macromol ; 186: 462-471, 2021 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-34271042

RESUMEN

A sensitive and efficient fluorescence labeling method was developed and validated for the microanalysis and detection of polysaccharides. Fluorescein isothiocyanate (FITC) was successfully labeled on mulberry fruit polysaccharides (MFP) through a reductive amination reaction with the assistant of tyramine. The fluorescent labeled polysaccharides (FMFP) was identified by fluorescence, UV-visible, flourier transform infrared (FT-IR) and 1H NMR spectrum. Results demonstrated that the labeling efficiency of FMFP was 0.32%, and the FMFP was stable in simulated digestion fluid without cytotoxicity. The pharmacokinetics and biodistribution after administration were analyzed in rats, which indicated that the FMFP obtained could be absorbed in a short time (tmax 0.50 h) but eliminated slowly (t1/2 8.77 ± 1.38 h). At 24 h after administration, the polysaccharide could be tested mainly in intestine, stomach, liver and kidney. The FITC labeling method lays a foundation for investigating the absorption and metabolism of MFP, and provides references for the microanalysis research of bioactive polysaccharides.


Asunto(s)
Fluoresceína-5-Isotiocianato/farmacocinética , Colorantes Fluorescentes/farmacocinética , Morus , Polisacáridos/farmacocinética , Administración Oral , Animales , Disponibilidad Biológica , Digestión , Fluoresceína-5-Isotiocianato/química , Colorantes Fluorescentes/química , Frutas , Masculino , Microquímica , Morus/química , Polisacáridos/química , Polisacáridos/aislamiento & purificación , Espectroscopía de Protones por Resonancia Magnética , Ratas Sprague-Dawley , Espectrometría de Fluorescencia , Espectroscopía Infrarroja por Transformada de Fourier , Distribución Tisular
5.
Eur J Pharm Biopharm ; 163: 38-48, 2021 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-33785416

RESUMEN

The oral administration of drugs remains a challenge due to rapid enzymatic degradation and minimal absorption in the gastrointestinal tract. Mechanical forces, namely hypergravity, can interfere with cellular integrity and drug absorption, and there is no study describing its influence in the intestinal permeability. In this work, it was studied the effect of hypergravity on intestinal Caco-2 cells and its influence in the intestinal permeability of different nanoformulations and molecules. It was shown that the cellular metabolic activity and integrity were maintained after exposure to different gravity-levels (g-levels). Expression of important drug transporters and tight junctions' proteins was evaluated and, most proteins demonstrated a switch of behavior in their expression. Furthermore, paracellular transport of FITC-Dextran showed to significantly increase with hypergravity, which agrees with the decrease of transepithelial electrical resistance and the increase of claudin-2 at higher g-levels. The diffusion of camptothecin released from polymeric micelles revealed a significant decrease, which agrees with the increased expression of the P-gp observed with the increase in g-levels, responsible for pumping this drug out. The neonatal Fc receptor-mediated transport of albumin-functionalized nanoparticles loaded with insulin showed no significant changes when increasing the g-levels. Thus, this study supports the effect of hypergravity on intestinal permeability is dependent on the molecule studied and the mechanism by which it is absorbed in the intestine.


Asunto(s)
Hipergravedad , Absorción Intestinal , Mucosa Intestinal/metabolismo , Administración Oral , Células CACO-2 , Camptotecina/administración & dosificación , Camptotecina/química , Camptotecina/farmacocinética , Dextranos/administración & dosificación , Dextranos/química , Dextranos/farmacocinética , Portadores de Fármacos/química , Impedancia Eléctrica , Fluoresceína-5-Isotiocianato/administración & dosificación , Fluoresceína-5-Isotiocianato/análogos & derivados , Fluoresceína-5-Isotiocianato/química , Fluoresceína-5-Isotiocianato/farmacocinética , Humanos , Insulina/administración & dosificación , Insulina/química , Insulina/farmacocinética , Micelas , Peso Molecular , Nanopartículas/química , Permeabilidad , Uniones Estrechas/metabolismo
6.
Nat Commun ; 12(1): 658, 2021 01 28.
Artículo en Inglés | MEDLINE | ID: mdl-33510169

RESUMEN

A microneedle array is an attractive option for a minimally invasive means to break through the skin barrier for efficient transdermal drug delivery. Here, we report the applications of solid polymer-based ion-conductive porous microneedles (PMN) containing interconnected micropores for improving iontophoresis, which is a technique of enhancing transdermal molecular transport by a direct current through the skin. The PMN modified with a charged hydrogel brings three innovative advantages in iontophoresis at once: (1) lowering the transdermal resistance by low-invasive puncture of the highly resistive stratum corneum, (2) transporting of larger molecules through the interconnected micropores, and (3) generating electroosmotic flow (EOF). In particular, the PMN-generated EOF greatly enhances the transdermal molecular penetration or extraction, similarly to the flow induced by external pressure. The enhanced efficiencies of the EOF-assisted delivery of a model drug (dextran) and of the extraction of glucose are demonstrated using a pig skin sample. Furthermore, the powering of the PMN-based transdermal EOF system by a built-in enzymatic biobattery (fructose / O2 battery) is also demonstrated as a possible totally organic iontophoresis patch.


Asunto(s)
Sistemas de Liberación de Medicamentos/instrumentación , Sistemas de Liberación de Medicamentos/métodos , Epidermis/metabolismo , Piel/metabolismo , Administración Cutánea , Animales , Dextranos/administración & dosificación , Dextranos/metabolismo , Dextranos/farmacocinética , Electroósmosis , Fluoresceína-5-Isotiocianato/administración & dosificación , Fluoresceína-5-Isotiocianato/análogos & derivados , Fluoresceína-5-Isotiocianato/metabolismo , Fluoresceína-5-Isotiocianato/farmacocinética , Glucosa/administración & dosificación , Glucosa/metabolismo , Glucosa/farmacocinética , Humanos , Iontoforesis/instrumentación , Iontoforesis/métodos , Masculino , Microinyecciones , Agujas , Moléculas de Patrón Molecular Asociado a Patógenos/administración & dosificación , Moléculas de Patrón Molecular Asociado a Patógenos/metabolismo , Moléculas de Patrón Molecular Asociado a Patógenos/farmacocinética , Porosidad , Porcinos
7.
Eur J Pharm Biopharm ; 158: 313-322, 2021 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-33259898

RESUMEN

Alginate can be gently crosslinked by calcium into hydrogels and microspheres for the encapsulation and release of proteins and drugs. However, the release is often over short periods unless alginate is also covalently modified or crosslinked. This research aims to sustain the release of encapsulated model drug FITC-dextran by covalently crosslinking alginate with short oligomers DNA because evidence suggests that DNA may also interact with alginate to further increase effective crosslinking. Furthermore, modulating the release of drugs from alginate in response to specific proteins could tailor release profiles to improve patient treatment. This research develops a DNA-crosslinked alginate hydrogel and layered alginate microspheres to encapsulate and then sustain the release FITC-dextran (model drug). An aptamer sequence to hen egg-white lysozyme is included in one DNA strand to allow for the disruption of the crosslinks by interactions with human lysozyme. Alginate was covalently modified with complementary strands of DNA to crosslink the alginate into hydrogels, which had increased crosslinking density when re-swollen (in comparison to controls crosslinked with PEG) and could sustained the release of encapsulated FITC-dextran. When an aptamer sequence for hen lysozyme was included in the DNA crosslinks, the hydrogels decrosslinked when incubated in human lysozyme for 60 days. In addition, calcium alginate microspheres were coated with 3 alternating layers of poly-Lysine, DNA-crosslinked alginate, and poly-L-lysine. FITC-dextran loaded into the microspheres released in a sustained manner past 30 days (into PBS at 37 °C) and would likely continue to release for far longer had the studies continued. When incubated with 3 µM of human lysozyme, a burst release of FITC-dextran occurred from both the hydrogels and microspheres, with no changes in the controls. The increased release was in bursts followed by similar sustained release rates suggesting that the human lysozyme temporarily disrupted the DNA crosslinks which were then re-established or were influenced by interactions between DNA and alginate. Importantly, covalently bound complementary strands of DNA could crosslink the alginate and additional interactions appeared to further sustain the release of encapsulated therapeutics.


Asunto(s)
Dextranos/farmacocinética , Portadores de Fármacos/química , Fluoresceína-5-Isotiocianato/análogos & derivados , Microesferas , Alginatos/química , Aptámeros de Nucleótidos/química , Reactivos de Enlaces Cruzados , ADN/química , Preparaciones de Acción Retardada/administración & dosificación , Preparaciones de Acción Retardada/farmacocinética , Dextranos/administración & dosificación , Composición de Medicamentos/métodos , Liberación de Fármacos , Fluoresceína-5-Isotiocianato/administración & dosificación , Fluoresceína-5-Isotiocianato/farmacocinética , Hidrogeles/química , Tamaño de la Partícula
8.
Biol Pharm Bull ; 43(11): 1729-1734, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33132318

RESUMEN

Technologies that overcome the barrier presented by vascular endothelial cells are needed to facilitate targeted delivery of drugs into tissue parenchyma by intravenous administration. We previously reported that weak electric current treatment (ET: 0.3-0.5 mA/cm2) applied onto skin tissue in a transdermal drug delivery technique termed iontophoresis induces cleavage of intercellular junctions that results in permeation of macromolecules such as small interfering RNA and cytosine-phosphate-guanine (CpG) oligonucleotide through the intercellular space. Based on these findings, we hypothesized that application of ET to blood vessels could promote cleavage of intercellular junctions that artificially induces increase in vascular permeability to enhance extravasation of drugs from the vessels into target tissue parenchyma. Here we investigated the effect of ET (0.34 mA/cm2) on vascular permeability using embryonated chicken eggs, which have blood vessels in the chorioallantoic membrane (CAM), as an animal model. ET onto the CAM of the eggs significantly increased extravasation of intravenously injected calcein (M.W. 622.6), a low molecular weight compound model, and the macromolecule fluorescein isothiocyanate (FITC)-dextran (M.W. 10000). ET-mediated promotion of penetration of FITC-dextran through vascular endothelial cells was also observed in transwell permeability assay using monolayer of human umbilical vein endothelial cells without induction of obvious cellular damage. Confocal microscopy detected remarkable fluorescence derived from injected FITC-dextran in blood vessel walls. These results in embryonated chicken eggs suggest that ET onto blood vessels could artificially enhance vascular permeability to facilitate extravasation of macromolecules from blood vessels.


Asunto(s)
Permeabilidad Capilar , Dextranos/administración & dosificación , Endotelio Vascular/metabolismo , Fluoresceína-5-Isotiocianato/análogos & derivados , Animales , Pollos , Membrana Corioalantoides/irrigación sanguínea , Dextranos/farmacocinética , Estimulación Eléctrica , Endotelio Vascular/citología , Fluoresceína-5-Isotiocianato/administración & dosificación , Fluoresceína-5-Isotiocianato/farmacocinética , Células Endoteliales de la Vena Umbilical Humana , Humanos , Inyecciones Intravenosas , Microscopía Confocal
9.
Physiol Rep ; 8(20): e14629, 2020 10.
Artículo en Inglés | MEDLINE | ID: mdl-33113283

RESUMEN

Impaired intestinal permeability can induce systemic inflammation and metabolic disturbance. However, the effect of impaired intestinal permeability on metabolic function in the skeletal muscle is unknown. Dietary polysorbate 80 (PS80), a common emulsifier, has been shown to impair intestinal permeability in mice. Here, we investigated the effect of PS80-induced intestinal permeability on glucose tolerance with metabolic signaling in the skeletal muscle. Male ICR mice were divided into control and PS80 groups. In the PS80 group, PS80 was contained in the drinking water at 1% (w/v). After 4 weeks, plasma fluorescein isothiocyanate (FITC) intensity was measured after orally administering FITC-dextran. Half of the mice in each group underwent running exercises. Metabolic and inflammatory parameters were examined in the blood and skeletal muscle. Plasma FITC and lipopolysaccharide levels were higher in the PS80 group than the control group (p < .01, p = .085). The expression of tumor necrosis factor-α in the skeletal muscle was increased upon PS80 administration (p < .05). Although the homeostasis model assessment ratio was higher in the PS80-fed mice (p < .05), insulin-signaling activity in the muscle did not differ between groups. Muscular pH, mitochondrial cytochrome oxidase activity, and glycogen content after exercise were lower in the PS80 group (p < .05) than the control group. There was a negative correlation between plasma FITC and muscle glycogen levels in the exercised groups (r = -.60, p < .05). These results suggest that daily PS80 intake induces intestinal permeability, leading to glucose intolerance and mitochondrial dysfunction in the skeletal muscle.


Asunto(s)
Absorción Intestinal/efectos de los fármacos , Músculo Esquelético/efectos de los fármacos , Polisorbatos/farmacología , Tensoactivos/farmacología , Animales , Complejo IV de Transporte de Electrones/metabolismo , Fluoresceína-5-Isotiocianato/farmacocinética , Glucógeno/metabolismo , Lipopolisacáridos/sangre , Masculino , Ratones , Ratones Endogámicos ICR , Mitocondrias Musculares/metabolismo , Músculo Esquelético/metabolismo , Músculo Esquelético/fisiología , Polisorbatos/efectos adversos , Carrera , Tensoactivos/efectos adversos , Factor de Necrosis Tumoral alfa/metabolismo
10.
Biomed Res Int ; 2020: 4012194, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32550231

RESUMEN

pH is a critical indicator of bone physiological function and disease status; however, noninvasive and real-time sensing of bone pH in vivo has been a challenge. Here, we synthesized a bone pH sensor by labeling alendronate with the H+-sensitive dye fluorescein isothiocyanate (Aln-FITC). Aln-FITC showed selective affinity for hydroxyapatite (HAp) rather than other calcium materials. An in vivo biodistribution study showed that Aln-FITC can be rapidly and specifically delivered to rat bones after caudal vein injection, and the fluorescence lasted for at least 12 h. The fluorescence intensity of Aln-FITC binding to HAp linearly decreased when the pH changed from 6 to 12. This finding was further confirmed on bone blocks and perfused bone when the pH changed from 6.8 to 7.4, indicating unique pH-responsive characteristics in the bone microenvironment. Aln-FITC was then preliminarily applied to evaluate the changes in bone pH in a nude mouse acidosis model. Our results demonstrated that Aln-FITC might have the potential for minimally invasive and real-time in vivo bone pH sensing in preclinical studies of bone healing, metabolism, and cancer mechanisms.


Asunto(s)
Alendronato , Huesos , Durapatita , Fluoresceína-5-Isotiocianato , Concentración de Iones de Hidrógeno , Alendronato/análisis , Alendronato/química , Alendronato/farmacocinética , Animales , Huesos/química , Huesos/metabolismo , Durapatita/química , Durapatita/metabolismo , Fluoresceína-5-Isotiocianato/análisis , Fluoresceína-5-Isotiocianato/química , Fluoresceína-5-Isotiocianato/farmacocinética , Humanos , Masculino , Ratones Desnudos , Monitoreo Fisiológico , Imagen Óptica , Ratas , Ratas Sprague-Dawley , Distribución Tisular
11.
Int J Pharm ; 584: 119455, 2020 Jun 30.
Artículo en Inglés | MEDLINE | ID: mdl-32464235

RESUMEN

Chronic kidney disease (CKD) is one of the leading public health problems worldwide and finally progresses to end-stage renal disease. The therapeutic options of CKD are very limited. Thus, development of drug delivery systems specific-targeting to kidney may offer more options. Here we developed an efficient kidney-targeted drug delivery system using a FITC labeled renal tubular-targeting peptide modified PLGA-PEG nanoparticles and investigated the intrarenal distribution and cell-type binding. We found that the modified nanoparticles with an approximate diameter of 200 nm exhibited the highest binding capacity with HK-2 cells and fluorescence and immunohistochemical analysis showed they mainly localized in renal proximal tubules by passing through the basolateral side. Furthermore, these kidney-specific nanoparticles could significantly enhance the therapeutic effects of asiatic acid, an insoluble triterpenoid compound as drug delivery carriers. In conclusion, these results suggest the potential of the peptide modified PLGA-PEG nanoparticles as kidneytargeted drug delivery system to proximal tubular cells in treatment of CKD.


Asunto(s)
Sistemas de Liberación de Medicamentos , Enfermedades Renales/tratamiento farmacológico , Nanopartículas/administración & dosificación , Triterpenos Pentacíclicos/administración & dosificación , Péptidos/administración & dosificación , Poliésteres/administración & dosificación , Polietilenglicoles/administración & dosificación , Animales , Línea Celular , Supervivencia Celular/efectos de los fármacos , Colágeno Tipo III/metabolismo , Fluoresceína-5-Isotiocianato/administración & dosificación , Fluoresceína-5-Isotiocianato/farmacocinética , Humanos , Riñón/efectos de los fármacos , Riñón/metabolismo , Enfermedades Renales/metabolismo , Masculino , Triterpenos Pentacíclicos/farmacocinética , Péptidos/farmacocinética , Poliésteres/farmacocinética , Polietilenglicoles/farmacocinética , Ratas Sprague-Dawley , Factor de Crecimiento Transformador beta1/metabolismo
12.
Poult Sci ; 99(3): 1687-1692, 2020 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-32115037

RESUMEN

The purpose of this study was to evaluate heat stress as a model to induce gastrointestinal leakage in broiler chickens. On the day of hatch, 320 chicks were allocated into 8 environmental chambers, 4 thermoneutral (TN) and 4 continuous heat stress (HS). Each chamber was divided into 2 pens containing separate feeders and water jugs (8 replicates per treatment, 20 birds/pen). The environment was established to simulate production setting as best possible for the first 21 D. A gradual reduction of temperature from 32°C to 24°C with relative humidity at 55 ± 5% was adopted for the first 21 D. At the time of HS, the HS groups were exposed to 35°C from Day 21 to 42, while thermoneutral ones were maintained at 24°C from Day 21 to 42. Chickens were equipped with a Thermochron temperature logger for continuous monitoring of core body temperature. The environmental temperature and relative humidity were continuously recorded. Fluorescein isothiocyanate-dextran (FITC-d) was orally gavaged to 2 chickens/replicate (n = 16) randomly selected on days 21, 28, 35, and 42. After 1 h of oral gavage, blood samples were collected to determine the passage of FITC-d. Tibias were removed from all chickens to evaluate break strength only on 21 D and 42 D (before HS and at the end of the trial). Performance parameters were evaluated weekly from 21 D to the end of the trial. Body temperature was significantly (P < 0.05) increased after 2 h of starting HS and remained that way until the end of the study. Chronic HS caused an increase in core body temperature which decreased feed intake, body weight, and feed efficiency (28, 35, and 42 D) when compared with control TN chickens. Similarly, serum FITC-d was significantly increased in HS chickens at all points of evaluation. Chronic HS also caused a significant reduction of bone strength at 42 D when compared with the control chickens. The results from the present study suggest that HS can be a robust model to induce gut leakage in broiler chickens.


Asunto(s)
Tracto Gastrointestinal/fisiopatología , Trastornos de Estrés por Calor/veterinaria , Permeabilidad , Animales , Animales Recién Nacidos , Temperatura Corporal , Densidad Ósea , Pollos , Dextranos/farmacocinética , Modelos Animales de Enfermedad , Fluoresceína-5-Isotiocianato/análogos & derivados , Fluoresceína-5-Isotiocianato/farmacocinética , Calor/efectos adversos
13.
J Crohns Colitis ; 14(7): 974-994, 2020 Jul 30.
Artículo en Inglés | MEDLINE | ID: mdl-32003421

RESUMEN

BACKGROUND AND AIMS: There is evidence for a disturbed intestinal barrier function in inflammatory bowel diseases [IBD] but the underlying mechanisms are unclear. Because mucins represent the major components of the mucus barrier and disturbed mucin expression is reported in the colon of IBD patients, we studied the association between mucin expression, inflammation and intestinal permeability in experimental colitis. METHODS: We quantified 4-kDa FITC-dextran intestinal permeability and the expression of cytokines, mucins, junctional and polarity proteins at dedicated time points in the adoptive T cell transfer and dextran sodium sulfate [DSS]-induced colitis models. Mucin expression was also validated in biopsies from IBD patients. RESULTS: In both animal models, the course of colitis was associated with increased interleukin-1ß [IL-1ß] and tumour necrosis factor-α [TNF-α] expression and increased Muc1 and Muc13 expression. In the T cell transfer model, a gradually increasing Muc1 expression coincided with gradually increasing 4-kDa FITC-dextran intestinal permeability and correlated with enhanced IL-1ß expression. In the DSS model, Muc13 expression coincided with rapidly increased 4-kDa FITC-dextran intestinal permeability and correlated with TNF-α and Muc1 overexpression. Moreover, a significant association was observed between Muc1, Cldn1, Ocln, Par3 and aPKCζ expression in the T cell transfer model and between Muc13, Cldn1, Jam2, Tjp2, aPkcζ, Crb3 and Scrib expression in the DSS model. Additionally, MUC1 and MUC13 expression was upregulated in inflamed mucosa of IBD patients. CONCLUSIONS: Aberrantly expressed MUC1 and MUC13 might be involved in intestinal barrier dysfunction upon inflammation by affecting junctional and cell polarity proteins, indicating their potential as therapeutic targets in IBD.


Asunto(s)
Colitis Ulcerosa/fisiopatología , Colitis/fisiopatología , Enfermedad de Crohn/fisiopatología , Citocinas/metabolismo , Mucinas/genética , Mucinas/metabolismo , Actinas/metabolismo , Animales , Linfocitos T CD4-Positivos/trasplante , Moléculas de Adhesión Celular/genética , Colitis/inducido químicamente , Colitis/inmunología , Colitis Ulcerosa/genética , Colitis Ulcerosa/metabolismo , Enfermedad de Crohn/genética , Enfermedad de Crohn/metabolismo , Sulfato de Dextran , Dextranos/farmacocinética , Modelos Animales de Enfermedad , Femenino , Fluoresceína-5-Isotiocianato/análogos & derivados , Fluoresceína-5-Isotiocianato/farmacocinética , Humanos , Interleucina-10/metabolismo , Interleucina-1beta/metabolismo , Interleucina-6/metabolismo , Mucosa Intestinal/fisiopatología , Masculino , Ratones Endogámicos BALB C , Ratones SCID , Quinasa de Cadena Ligera de Miosina/genética , Permeabilidad , Peroxidasa/metabolismo , Proteínas de Uniones Estrechas/genética , Factor de Necrosis Tumoral alfa/metabolismo
14.
Int J Pharm ; 577: 119044, 2020 Mar 15.
Artículo en Inglés | MEDLINE | ID: mdl-31954866

RESUMEN

This research aims to investigate the potential of N-[4-[1-(3-Aminopropyl)-2-hydroxy-2-nitrosohydrazino]butyl]-1,3-propanediamine (SPM-NONOate) for promoting the absorption of poorly absorbed macromolecules delivered by intrapulmonary route. Influence of SPM-NONOate on the drug absorption was characterized by using a series of fluorescein isothiocyanate-labeled dextrans (FDs) as affordable models of hydrophilic macromolecules with established tools for quantitative analysis. SPM-NONOate increased concentration-dependently within 1-10 mM the pulmonary absorptions of FDs in rats. Moreover, this promoting effect varied with the molecular weight of FDs, and the largest absorption enhancement effect was obtained for FD70. SPM-NONOate also showed promising enhancement potential on the absorption of some therapeutic peptides, where obvious hypoglycemic and hypocalcemic effects were observed after intrapulmonary delivery of insulin and calcitionin, respectively, with SPM-NONOate to rats. The safety of SPM-NONOate was confirmed based on measurement of some biological markers in bronchoalveolar lavage fluid (BALF) of rats. Additionally, mechanism underling the absorption enhancement action of SPM-NONOate was explored by combinatorial administration of FD4 and SPM-NONOate with various scavengers and generator to rat lungs. Results indicated that NO released from SPM-NONOate induced the enhancement in the drug absorption, and peroxynitrate, a NO metabolite, possibly participated in the absorption enhancing action of SPM-NONOate.


Asunto(s)
Dextranos/administración & dosificación , Fluoresceína-5-Isotiocianato/análogos & derivados , Óxido Nítrico/metabolismo , Péptidos/administración & dosificación , Espermina/análogos & derivados , Animales , Líquido del Lavado Bronquioalveolar , Calcitonina/administración & dosificación , Calcitonina/farmacocinética , Calcitonina/farmacología , Dextranos/química , Dextranos/farmacocinética , Sistemas de Liberación de Medicamentos , Fluoresceína-5-Isotiocianato/administración & dosificación , Fluoresceína-5-Isotiocianato/química , Fluoresceína-5-Isotiocianato/farmacocinética , Insulina/administración & dosificación , Insulina/farmacocinética , Insulina/farmacología , Masculino , Peso Molecular , Péptidos/química , Péptidos/farmacocinética , Ratas , Ratas Sprague-Dawley , Absorción a través del Sistema Respiratorio , Espermina/química
15.
Nat Prod Res ; 34(22): 3253-3256, 2020 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-30676779

RESUMEN

ß-glucans are a heterogeneous group of natural polysaccharides. They are ubiquitously found in bacterial or fungal cell walls, cereals, seaweed, and mushrooms. The beneficial role of ß-glucan in tumor, insulin resistance, dyslipidemia, hypertension, and obesity is being continuously documented. Ample evidence showed that ß-glucan could act on several receptors, such as Dectin, complement receptor (CR3), TLR-2, 4, 6 and scavenger. Based on the above, we wanted to explore whether agaricus bisporus-derived ß-glucan acted on these receptors on Raw 264.7 macrophages and 3T3-L1 adipocytes.


Asunto(s)
Adipocitos/efectos de los fármacos , Agaricus/química , Antígenos CD36/metabolismo , Macrófagos/efectos de los fármacos , beta-Glucanos/farmacología , Células 3T3-L1 , Adipocitos/metabolismo , Animales , Cromatografía Líquida de Alta Presión , Citometría de Flujo/instrumentación , Fluoresceína-5-Isotiocianato/farmacocinética , Polisacáridos Fúngicos/farmacocinética , Polisacáridos Fúngicos/farmacología , Macrófagos/metabolismo , Ratones , Células RAW 264.7 , beta-Glucanos/farmacocinética
16.
Lymphat Res Biol ; 18(1): 16-21, 2020 02.
Artículo en Inglés | MEDLINE | ID: mdl-31233351

RESUMEN

Background: Radiation therapy has been applied to prolong the duration of lymphedema. This study aimed to evaluate the effect of radiation on the development of lymphedema in a mouse hindlimb model. Methods and Results: A total of 24 Balb/c mice underwent the right popliteal lymph node excision and the afferent and efferent lymphatics blockage. The radiation group (n = 12) received a single 20 Gy radiation 1 day before surgery in the right hindlimb of each mouse, whereas the control group (n = 12) only received surgery without radiation. The right hindpaw thickness of each mouse was measured twice a week for 4 weeks. Fluorescence microscopy images using fluorescein isothiocyanate-dextran tracer were obtained once weekly. Immunohistochemical (IHC) staining images using anti-lymphatic vessel endothelial hyaluronan receptor-1 (anti-LYVE-1) were obtained at 4 weeks after surgery. The radiation group showed significant increase in the thickness of the right hind paws from 0.5 to 2 weeks compared with the control group. As for fluorescence lymphography, the radiation group showed a lower number of regenerated lymphatics and more congestion of tracers in the operated limb at the surgery sites at 1, 2, 3, and 4 weeks after surgery. For the IHC analysis, the radiation group showed a lower number of regenerated lymphatics per high-power field at the surgery site than the control group. Conclusion: Radiation therapy transiently aggravated the extent of lymphedema by inhibiting regenerated lymphatics in a mouse hindlimb model. However, it did not prolong the duration of lymphedema because the cutaneous interstitial flow contributes to the lymphatic fluid clearance.


Asunto(s)
Rayos gamma/efectos adversos , Miembro Posterior/patología , Vasos Linfáticos/patología , Linfedema/patología , Animales , Biomarcadores/metabolismo , Dextranos/análisis , Dextranos/farmacocinética , Modelos Animales de Enfermedad , Femenino , Fluoresceína-5-Isotiocianato/análogos & derivados , Fluoresceína-5-Isotiocianato/análisis , Fluoresceína-5-Isotiocianato/farmacocinética , Colorantes Fluorescentes/análisis , Colorantes Fluorescentes/farmacocinética , Expresión Génica , Miembro Posterior/diagnóstico por imagen , Miembro Posterior/metabolismo , Humanos , Escisión del Ganglio Linfático/métodos , Ganglios Linfáticos/cirugía , Vasos Linfáticos/diagnóstico por imagen , Vasos Linfáticos/metabolismo , Linfedema/diagnóstico por imagen , Linfedema/radioterapia , Linfografía , Proteínas de Transporte de Membrana/genética , Proteínas de Transporte de Membrana/metabolismo , Ratones , Ratones Endogámicos BALB C
17.
Mol Pharm ; 17(1): 212-218, 2020 01 06.
Artículo en Inglés | MEDLINE | ID: mdl-31756103

RESUMEN

The present study sought to demonstrate the effect of dietary intake of medium-chain triacylglycerides (MCTs) on the intestinal absorption of a poorly permeable compound of intermediate molecular weight (FITC-dextran 4000 [FD-4]). As a model of MCTs, C8-C12 fatty acid triacylglyceride (COCONAD ML) was mainly used, and the dose strength of each triglyceride was set with consideration of the dietary ingestion dose (12.5 mg/rat). When FD-4 with MCTs dispersed in fasted state simulated intestinal fluid containing surfactants was administered into the rat jejunum, the intestinal absorption of FD-4 was significantly higher than when administered with a similar solution with or without corn oil (long-chain triglycerides). The effects of pretreatment by MCT lipolysis, inhibition of endogenous lipases, and different dose timings of MCTs and FD-4 on the intestinal absorption of FD-4 indicated that medium-chain fatty acids, such as caprylic acid and capric acid, released from MCTs by lipolysis in the small intestine significantly enhanced the intestinal absorption of FD-4, but the effect was transient. In addition, a similar effect was observed when MCTs were dispersed in soymilk, although large interindividual variation was detected. These findings suggested that dietary intake of MCTs might affect the intestinal absorption of poorly permeable compounds.


Asunto(s)
Absorción Intestinal/efectos de los fármacos , Lipólisis/efectos de los fármacos , Triglicéridos/administración & dosificación , Animales , Caprilatos/administración & dosificación , Ácidos Decanoicos/administración & dosificación , Dextranos/sangre , Dextranos/farmacocinética , Dextranos/farmacología , Dietoterapia , Fluoresceína-5-Isotiocianato/análogos & derivados , Fluoresceína-5-Isotiocianato/farmacocinética , Fluoresceína-5-Isotiocianato/farmacología , Yeyuno/efectos de los fármacos , Yeyuno/enzimología , Yeyuno/metabolismo , Lipasa/antagonistas & inhibidores , Lipasa/farmacología , Masculino , Ratas , Ratas Sprague-Dawley , Leche de Soja/administración & dosificación , Triglicéridos/química
18.
Head Face Med ; 15(1): 27, 2019 Nov 11.
Artículo en Inglés | MEDLINE | ID: mdl-31711509

RESUMEN

BACKGROUND: Controlled release of proteins bound to conventional bone substitutes is still insufficient. Therefore, this study evaluates in-vitro release kinetics of the model protein FITC-BSA (fluorescein conjugated bovine serum albumine) from insoluble bovine collagenous bone matrices (ICBM) with different polymer coatings. Analyzes aim at comparing FITC-BSA release from uncoated versus coated ICBM over time to find bone substitute coatings with consistent release profiles. METHODS: Release kinetics of FITC-BSA from uncoated as well as coated ICBM with five different polymers (RESOMER R 203 H, RG 503 H, RG 504 H, RG 505, L 206 S) were measured over a period of 11 days (d). Measurements were conducted after 6 h (h), 12 h, 24 h, 3 d, 5 d, 7 d, 9 d and 11 d with six samples for each coated ICBM. Two groups were formed (1) with and (2) without medium change at times of measurement. For each group ANOVA with post-hoc Bonferroni testing was used. Scanning electron microscopy assessed morphologic differences between ICBM coating. RESULTS: In group 1 approx. 70% of FITC-BSA release from uncoated ICBM occurred after 6 h compared to approx. 50% in group 2. Only polymers with medium inherent viscosity, i.e. RESOMER RG 503 H, constantly showed significantly more FITC-BSA release throughout 11 d than uncoated ICBM (p = 0.007). The same was found for group 2 (p = 0.005). No significant differences between PLA and PLGA polymers were found. Scanning electron microscopy results indicate a weak adhesion of polymer coatings to ICBM explaining its rather weak retentive effect on overall FITC-BSA release. CONCLUSIONS: Medium molecular size polymers reduce the overall released FITC-BSA from ICBM over time. In clinical practice these polymers may prove ideal for bone substitute materials.


Asunto(s)
Sustitutos de Huesos , Fluoresceína-5-Isotiocianato/análogos & derivados , Polímeros , Albúmina Sérica Bovina , Animales , Sustitutos de Huesos/farmacocinética , Bovinos , Fluoresceína-5-Isotiocianato/farmacocinética , Cinética , Microscopía Electrónica de Rastreo , Albúmina Sérica Bovina/farmacocinética
19.
Int J Pharm ; 572: 118811, 2019 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-31678524

RESUMEN

Retinal disorders are leading causes of blindness. Still, treatment strategies are limited and the challenging anatomical barriers of the eye limit the evaluation and development of new therapeutics. Among these layers of barriers is the blood-retinal barrier, which separates the retina from the choroid by the Bruch's membrane. This work aimed to establish a 3D cellular model that recapitulates barrier properties of the BRB and diffusion through the vitreous, the main barriers encountered upon intravitreal injection. Several parameters were evaluated namely co-culture time of ARPE-19 and HUVECs and different biomaterial compositions of hydrogels to better mimic the human vitreous. The developed vitreous mimic has viscoelastic properties similar to human vitreous. Co-culture of human retinal and endothelial cells showed increased transepithelial resistance with longer co-culture times concomitant with reduced permeability to FITC-dextran 40 kDa. The proposed models lay the foundation of a platform for faster assessment of a large number of samples and without the use of animals.


Asunto(s)
Barrera Hematorretinal/citología , Células Endoteliales/citología , Modelos Biológicos , Alternativas a las Pruebas en Animales , Animales , Barrera Hematorretinal/metabolismo , Técnicas de Cocultivo , Dextranos/administración & dosificación , Dextranos/farmacocinética , Células Endoteliales/metabolismo , Fluoresceína-5-Isotiocianato/administración & dosificación , Fluoresceína-5-Isotiocianato/análogos & derivados , Fluoresceína-5-Isotiocianato/farmacocinética , Humanos , Inyecciones Intravítreas , Permeabilidad , Cuerpo Vítreo/metabolismo
20.
Sci Rep ; 9(1): 13439, 2019 09 17.
Artículo en Inglés | MEDLINE | ID: mdl-31530838

RESUMEN

Hollow titanium dioxide (TiO2) nanotubes offer substantially higher drug loading capacity and slower drug release kinetics compared to solid drug nanocarriers of comparable size. In this report, we load TiO2 nanotubes with iron oxide nanoparticles to facilitate site-specific magnetic guidance and drug delivery. We generate magnetic TiO2 nanotubes (TiO2NTs) by incorporating a ferrofluid containing Ø ≈ 10 nm iron oxide nanoparticles in planar sheets of weakly connected TiO2 nanotubes. After thermal annealing, the magnetic tubular arrays are loaded with therapeutic drugs and then sonicated to separate the nanotubes. We demonstrate that magnetic TiO2NTs are non-toxic for HeLa cells at therapeutic concentrations (≤200 µg/mL). Adhesion and endocytosis of magnetic nanotubes to a layer of HeLa cells are increased in the presence of a magnetic gradient field. As a proof-of-concept, we load the nanotubes with the topoisomerase inhibitor camptothecin and achieve a 90% killing efficiency. We also load the nanotubes with oligonucleotides for cell transfection and achieve 100% cellular uptake efficiency. Our results demonstrate the potential of magnetic TiO2NTs for a wide range of biomedical applications, including site-specific delivery of therapeutic drugs.


Asunto(s)
Portadores de Fármacos/administración & dosificación , Portadores de Fármacos/química , Sistemas de Liberación de Medicamentos/métodos , Nanotubos/química , Titanio/química , Camptotecina/administración & dosificación , Camptotecina/farmacocinética , Portadores de Fármacos/farmacocinética , Sistemas de Liberación de Medicamentos/instrumentación , Liberación de Fármacos , Compuestos Férricos/química , Fluoresceína-5-Isotiocianato/química , Fluoresceína-5-Isotiocianato/farmacocinética , Células HeLa , Humanos , Campos Magnéticos , Nanopartículas del Metal/química , Nanotubos/toxicidad , Espectroscopía de Fotoelectrones , Prueba de Estudio Conceptual , Inhibidores de Topoisomerasa I/administración & dosificación , Inhibidores de Topoisomerasa I/farmacocinética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...